Efficacy and safety of regimens used for the treatment of multicentric Castleman disease : A systematic review
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
OBJECTIVES: Treatment options for multicentric Castleman disease (MCD) remain limited. The only FDA-approved drug is siltuximab for idiopathic MCD (iMCD), but the response rate with siltuximab is less than 50%. We performed a systematic review to examine the efficacy and safety of various regimens used for the treatment of MCD.
METHODS: A database search on PubMed, Embase, Cochrane, Web of Science, and Clinicaltrials.gov using the terms "Castleman disease," "treatment outcome," and "patient safety" was done.
RESULTS AND CONCLUSIONS: Results from a randomized controlled trial and an extension study highlighted the efficacy and long-term safety of siltuximab for iMCD; other trials showed tocilizumab to be a suitable alternative. A recent trial reported high response rates with thalidomide in iMCD patients. Promising results were reported for bortezomib in relapsed/ refractory MCD. For human herpesvirus-8 (HHV8)-associated MCD, rituximab along with doxorubicin therapy followed by maintenance with zidovudine and valganciclovir is the most effective therapy. A single-arm trial has highlighted the potential role of tocilizumab in HHV8-MCD. Data for these regimens are limited and mostly comprise nonrandomized trials. Further research on emerging agents could have a major impact on the treatment of this rare disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
European journal of haematology - 109(2022), 4 vom: 30. Okt., Seite 309-320 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rehman, Mohammad Ebad Ur [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 13.09.2022 Date Revised 13.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.13823 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342914588 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342914588 | ||
| 003 | DE-627 | ||
| 005 | 20231226015218.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.13823 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1143.xml |
| 035 | |a (DE-627)NLM342914588 | ||
| 035 | |a (NLM)35770616 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rehman, Mohammad Ebad Ur |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of regimens used for the treatment of multicentric Castleman disease |b A systematic review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.09.2022 | ||
| 500 | |a Date Revised 13.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVES: Treatment options for multicentric Castleman disease (MCD) remain limited. The only FDA-approved drug is siltuximab for idiopathic MCD (iMCD), but the response rate with siltuximab is less than 50%. We performed a systematic review to examine the efficacy and safety of various regimens used for the treatment of MCD | ||
| 520 | |a METHODS: A database search on PubMed, Embase, Cochrane, Web of Science, and Clinicaltrials.gov using the terms "Castleman disease," "treatment outcome," and "patient safety" was done | ||
| 520 | |a RESULTS AND CONCLUSIONS: Results from a randomized controlled trial and an extension study highlighted the efficacy and long-term safety of siltuximab for iMCD; other trials showed tocilizumab to be a suitable alternative. A recent trial reported high response rates with thalidomide in iMCD patients. Promising results were reported for bortezomib in relapsed/ refractory MCD. For human herpesvirus-8 (HHV8)-associated MCD, rituximab along with doxorubicin therapy followed by maintenance with zidovudine and valganciclovir is the most effective therapy. A single-arm trial has highlighted the potential role of tocilizumab in HHV8-MCD. Data for these regimens are limited and mostly comprise nonrandomized trials. Further research on emerging agents could have a major impact on the treatment of this rare disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Castleman disease | |
| 650 | 4 | |a HHV8 | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a lymphadenopathy | |
| 650 | 4 | |a rituximab | |
| 650 | 4 | |a siltuximab | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Chattaraj, Asmi |e verfasserin |4 aut | |
| 700 | 1 | |a Neupane, Karun |e verfasserin |4 aut | |
| 700 | 1 | |a Rafae, Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Sajeel |e verfasserin |4 aut | |
| 700 | 1 | |a Basit, Jawad |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Atif |e verfasserin |4 aut | |
| 700 | 1 | |a Khouri, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Sudipto |e verfasserin |4 aut | |
| 700 | 1 | |a Anwer, Faiz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 109(2022), 4 vom: 30. Okt., Seite 309-320 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2022 |g number:4 |g day:30 |g month:10 |g pages:309-320 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.13823 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2022 |e 4 |b 30 |c 10 |h 309-320 | ||